Will GALEN become more RELEVANT?

Affiliations

¹ Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10065, USA.
² Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10065, USA. Electronic address: younesa@mskcc.org.

Comment

Gottfried von Keudell et al. Lancet Haematol. 2019 Aug.

. 2019 Aug;6(8):e391-e392.

doi: 10.1016/S2352-3026(19)30136-X. Epub 2019 Jul 8.

¹ Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10065, USA.
² Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10065, USA. Electronic address: younesa@mskcc.org.

No abstract available

Comment on

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R. Morschhauser F, et al. Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296423 Clinical Trial.